Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Net Margin (2016 - 2025)

Historic Net Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 9.04%.

  • Amphastar Pharmaceuticals' Net Margin fell 121000.0% to 9.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.81%, marking a year-over-year decrease of 76800.0%. This contributed to the annual value of 20.27% for FY2024, which is 8700.0% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Net Margin stood at 9.04% for Q3 2025, which was down 121000.0% from 17.79% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Net Margin's 5-year high stood at 27.59% during Q3 2021, with a 5-year trough of 3.84% in Q1 2021.
  • Moreover, its 5-year median value for Net Margin was 18.14% (2023), whereas its average is 17.53%.
  • In the last 5 years, Amphastar Pharmaceuticals' Net Margin surged by 225600bps in 2021 and then crashed by -142400bps in 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Margin (Quarter) stood at 16.52% in 2021, then soared by 31bps to 21.67% in 2022, then fell by -14bps to 18.74% in 2023, then fell by -25bps to 14.07% in 2024, then tumbled by -36bps to 9.04% in 2025.
  • Its Net Margin stands at 9.04% for Q3 2025, versus 17.79% for Q2 2025 and 14.83% for Q1 2025.